In MCF-7 breast cancer cells, LCL161 alone induces a slight induction of p52, which is potentiated if it is combined with TRAIL although the p52/p100 ratios are similar for both treatments (Fig 3B and 3C). The gene discussed is NFKB2; the disease is breast cancer.